**Globus Medical (GMED) Reports Strong Q1 Results Amid Stock Price Surge**
On [insert date], Globus Medical’s shares rose by 5.1%, closing at $79.23, driven by positive investor sentiment following its robust first quarter performance for 2026. The company reported adjusted earnings per share (EPS) of $1.12 and revenues of $759.9 million, both exceeding Zacks Consensus Estimates. Over the previous four weeks, GMED’s stock had seen a decline of 10.3%.
Globus Medical is anticipated to post earnings of $1.12 per share in its upcoming report, reflecting a 30.2% year-over-year increase. Revenues are projected to rise to $787.34 million, representing a 5.6% increase from the same quarter last year. Furthermore, the consensus EPS estimate has been revised 2.5% upward over the last month, suggesting potential ongoing strength in the stock.
In related news, Lucid Diagnostics Inc. (LUCD) also experienced a stock increase of 9.9%, closing at $1.08, despite a recent monthly return of -1.7%. LUCD’s EPS estimate for its next report has been adjusted up by 16.7% to -$0.04, indicating a significant improvement from the prior year.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
